These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21694929)

  • 1. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.
    Nodari S; Jao GT; Chiong JR
    Int J Nephrol Renovasc Dis; 2010; 3():51-60. PubMed ID: 21694929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaptans and hyponatremia in critical patients.
    D'Auria D; Marinosci GZ; De Benedictis G; Piazza O
    Transl Med UniSa; 2012 May; 3():1-14. PubMed ID: 23905047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
    Gaglio P; Marfo K; Chiodo J
    Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin receptor antagonists and their role in clinical medicine.
    Narayen G; Mandal SN
    Indian J Endocrinol Metab; 2012 Mar; 16(2):183-91. PubMed ID: 22470853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaptans for the treatment of hyponatremia.
    Robertson GL
    Nat Rev Endocrinol; 2011 Mar; 7(3):151-61. PubMed ID: 21283124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyponatremia in Heart Failure: Pathogenesis and Management.
    Rodriguez M; Hernandez M; Cheungpasitporn W; Kashani KB; Riaz I; Rangaswami J; Herzog E; Guglin M; Krittanawong C
    Curr Cardiol Rev; 2019; 15(4):252-261. PubMed ID: 30843491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms, risks, and new treatment options for hyponatremia.
    Ghali JK
    Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans.
    Malhotra I; Gopinath S; Janga KC; Greenberg S; Sharma SK; Tarkovsky R
    Case Rep Endocrinol; 2014; 2014():807054. PubMed ID: 24511399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.
    Vinod P; Krishnappa V; Chauvin AM; Khare A; Raina R
    Cardiol Res; 2017 Jun; 8(3):87-95. PubMed ID: 28725324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaptans: a promising therapy in the management of advanced cirrhosis.
    Ginès P
    J Hepatol; 2007 Jun; 46(6):1150-2. PubMed ID: 17445935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2 receptor antagonist; tolvaptan.
    Yi JH; Shin HJ; Kim HJ
    Electrolyte Blood Press; 2011 Dec; 9(2):50-4. PubMed ID: 22438856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
    Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.